National Institutes of Health, National Cancer Institute
Natural History Study of RASopathies
The Amalia Children’s Hospital of the Radboud University Medical Center in the Netherlands is doing a survey:
STUDY: Eating problems with NS spectrum disorders to find (better) treatment.
WHO: Parent of a NS child, or someone with NS yourself (does not matter what age), we would very much like to invite you to participate in our survey.
Even when feeding or eating problems were not present. The more people respond, the better the extent of eating problems will become clear.
It will take approx. 10 minutes. There is one wide table providing an overview per year, may be better to use a tablet or laptop.
The survey will stay open until the 1st of March 2022. **EXTENDED**
If the link does not open, please, copy the link to another window.
All information will be processed anonymously and securely.
If you have any questions, you can email directly at Dagmar.Tiemens@radboudumc.nl
- CLOSED: A Registry Study to Characterise Genetic and Pathway Biomarkers in Noonan Syndrome and Other RASopathy Patients – for more information click here.
- CLOSED: CASPER – The Cognitive and Social Profiling: Exploring Rasopathies (CASPER) study is a research study into a group of conditions called the RAS-MAPK pathway disorders. Go to http://www.bbmh.manchester.ac.uk/casper/AboutCASPER/ for a description.
If you would like to speak to the team at the University of Manchester for more information about the research, please contact;
If you would like to speak to the team at the Manchester Centre for Genomic Medicine, please contact;
tel: +44(0)161 701 5105
Palo Alto University
Participate in one of the first studies looking at the relationship between quality of life, behavior, and social cognition in RASopathy syndromes – for Noonan syndrome, and now open to any RASopathy.
• Parent online survey (~1hr)
• Child online survey & assessment (~1 hr)
• Parent phone survey (~30 minutes)
Who can participate?
• Any child with a RASopathy diagnosis and their family
• Ages 8-18
• Families from outside the US are welcome to participate!
• For children with limited reading levels, families may choose for only parents to participate.
• For families with limited internet access, we are happy to mail paper surveys.
Click here for flyer.
Paige Naylor, Doctoral Candidate
1 (504) 881-3925
This study is sponsored and monitored by the Palo Alto University IRB. The research team includes Wendy Packman, PhD, JD and Paige Naylor.
University of California, San Francisco
Lauren Weiss, PhD
University of California, San Francisco
Seeking participants for several studies
Study of brain and cognitive development in boys and girls with Noonan syndrome or NF1
Click HERE for the flyer for NF1 families interested in participating.
Compensation for travel and participation are provided!
Dr. Tamar Green’s Lab
CLOSED Survey: Healthcare information dissemination to and use by parents and/or caregivers of individuals with a rare disease.
My name is Ting Wang. I am a parent of a child with RASopathies mutation. My daughter Amelia is currently 3 years old. I am also a Ph.D. student at the School of Library and Information Management at Emporia State University in Emporia, KS USA.
I am conducting my PhD dissertation to learn about healthcare information dissemination to and use by parents and/or caregivers of individuals with a rare disease. I am interested in this study because I was struggling with acquiring healthcare information for caring for Amelia. I hope I can inform healthcare professionals about what information we need through doing this study that future parents of children with a rare disease will not struggle the same issue that I was facing.
If you are a family member of someone with a rare disease, will you please participate in this research? Please click on this link to the survey https://www.surveymonkey.com/r/TingWang
This survey will most likely take you about 10 minutes to complete. When you have completed the survey, your participation in this study will end. I will share the results with you by sending you a website link to the results documents. The survey has been approved by Institutional Review Boards about studying human subject. The survey will be closed on Aug 27th, 2021
I sincerely thank you very much for your participation in this project!
CLOSED: Hypertrophic Cardiomyopathy Study for Individuals with Noonan Syndrome with Multiple Lentigines / LEOPARD syndrome – for more information, click here.
Jane Messere, RN, Research Nurse
Children’s Hospital, Boston
Strengths and difficulties of children with genetic and neurodevelopmental differences
University of Minnesota, Twin Cities and University of Wisconsin, Madison
Approved for use by UMN IRB Effective on 6/20/2019
IRB Study Number: STUDY00006323
Researchers at UMN and UW are seeking research participants for a unique study on behavioral strengths and challenges of children ages 3-17 with any of the following diagnoses:
Autism Spectrum Disorder (ASD) Cardiofaciocutaneous (CFC) Syndrome Costello Syndrome (CS)
Fragile X Syndrome (FXS) Neurofibromatosis Type 1 (NF1) Noonan Syndrome (NS)
The purpose of the study is to learn how to help children build on their strengths and overcome challenges. By studying children with several different conditions, we can better understand the unique strengths and needs of children with each of these genetic or neurodevelopmental differences.
To complete this study, parents/caregivers will be asked to complete a 15-20 minute survey about their child’s day-to-day behavior. Families will be entered into a drawing for prizes:
1 Grand prize: $100 gift card
1 Second prize: $50 gift card
2 Third prizes: $25 gift card
For a flyer, click here
Alli Foy, MS and Rene Pierpont, PhD, LP
University of Minnesota Medical Center
Phone: (608) 709-9067
St. Louis – Washington University
The Neurofibromatosis Type 1 Patient Registry (NPR1) is currently recruiting both adults and children with NF1 for a childhood brain tumor study. The goal of this study is to identify differences in medical, social, demographic, and birth characteristics of children who develop childhood brain tumors compared to those who do not develop these tumors. We are looking for individuals with NF1 who either (1) HAVE previously been diagnosed with a brain tumor younger than age 18 years or (2) HAVE NEVER had a brain tumor. For more information click here: https://nf1registry.
Completing the online questionnaire/registration will take approximately 30 minutes of your time.
A Registry Study to Characterize Genetic and Pathway Biomarkers in Noonan Syndrome and Other RASopathy patients – for more information, click here.
Meghan Mac Neal, MS, CGC, MPH
Icahn School of Medicine at Mount Sinai
UPMC Children’s Hospital of Pittsburgh
Participate in a research study evaluating the characteristics of brain and spinal cord tumors (cancers) that occur in children, adolescents, and adults with all types of RASopathies except for Neurofibromatosis type 1 (NF1).
Study includes 1) permission to get and review clinical and imaging information from medical records obtained as part of standard of care at your local hospital 2) permission to use leftover tumor samples (if available from previous surgeries) and to collect some saliva
Dr. Alberto Broniscer, MD MS
More info HERE
Children’s Hospital, Philadelphia (CHOP)
A sleep research study to help develop a new pediatric sleep health survey to better understand how sleep health relates to RASopathies.
For parents of individuals with a RASopathy to complete a 10-15 minute online survey. Affected children between the ages of 8 and 17 may be able to participate in the study by answering the survey, as well. Anyone who understands English is eligible to participate (it is not limited to the United States).
Link to the consent and survey: https://redcap.chop.edu/
Children’s National Hospital, Dr. Andrew Dauber
Research study testing an experimental medication: Vosoritide for Selected Genetic Causes of Short Stature
Webinar about the trial is Here
Flyer with more information is Here
If you are a researcher who is conducting a clinical trial, please contact us.